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ttp://dx.doi.org/10.1016/j.ajpath.2014.09.009In this study, we aimed to evaluate the effects of exenatide (EXE) treatment on exocrine pancreas of
nonhuman primates. To this end, 52 baboons (Papio hamadryas) underwent partial pancreatectomy, followed
by continuous infusion of EXE or saline (SAL) for 14 weeks. Histological analysis, immunohistochemistry,
Computer Assisted Stereology Toolbox morphometry, and immunoﬂuorescence staining were performed at
baseline and after treatment. The EXE treatment did not induce pancreatitis, parenchymal or periductal in-
ﬂammatory cell accumulation, ductal hyperplasia, or dysplastic lesions/pancreatic intraepithelial neoplasia.
At study end, Ki-67epositive (proliferating) acinar cell number did not change, compared with baseline, in
either group. Ki-67epositiveductal cells increasedafter EXE treatment (PZ0.04).However, thechange inKi-
67epositive ductal cell number did not differ signiﬁcantly between the EXE and SALgroups (PZ 0.13).M-30e
positive (apoptotic) acinar and ductal cell number did not change after SAL or EXE treatment. No changes in
ductal density and volume were observed after EXE or SAL. Interestingly, by triple-immunoﬂuorescence
staining, we detected c-kit (a marker of cell transdifferentiation) positive ductal cells co-expressing insulin
in ducts only in the EXE group at study end, suggesting that EXEmay promote the differentiation of ductal cells
toward a b-cell phenotype. In conclusion, 14 weeks of EXE treatment did not exert any negative effect on
exocrine pancreas, by inducing either pancreatic inﬂammation or hyperplasia/dysplasia in nonhuman pri-
mates. (Am J Pathol 2015, 185: 139e150; http://dx.doi.org/10.1016/j.ajpath.2014.09.009)1 DK080148 (F.F.), Amylin/Lilly
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Fiorentino et alGlucagon-like peptide-1 (GLP-1) receptor agonists and
dipeptidyl peptidase-IV (DPP-IV) inhibitors represent new
classes of therapeutic agents for type 2 diabetes mellitus
treatment acting by augmenting b-cell function while
decreasing food intake and body weight.1e7
Isolated cases of pancreatitis have been reported in dia-
betic patients treated with GLP-1 receptor agonists and
DPP-IV inhibitors, prompting the US Food and Drug
Administration to issue alerts on possible adverse effects.8
Acute pancreatitis is a severe clinical condition character-
ized by pancreatic pathological changes and increased
serum amylase and lipase levels. Obstructive gallstone dis-
ease, alcohol abuse, hypertriglyceridemia, obesity, and type
2 diabetes mellitus are the most common risk factors for
pancreatitis and pancreatic cancer.9e11
Although pancreatitis and pancreatic cancer have been
suggested to be more frequent in diabetic patients treated
with GLP-1ebased therapies, the methodologically hetero-
geneous literature available does not support a ﬁrm
conclusion on whether GLP-1 receptor agonists or DPP-IV
inhibitors are directly implicated in pancreatitis or pancre-
atic cancer.8,12e25 Animal studies designed to examine the
effect of GLP-1ebased therapies on exocrine pancreas have
also yielded conﬂicting results.26e31
In this study, we directly evaluated whether the GLP-1
receptor agonist exenatide (EXE) can promote inﬂammation/
pancreatitis and hyperplasia/dysplasia in exocrine pancreas
of baboons. Baboons have interesting genetic and physio-
logical similarity to humans, develop similar pathological
features, and represent a valuable model to study human
diseases, such as insulin resistance, obesity, and type 2 dia-
betes mellitus.32e38
Materials and Methods
Study Population and Analytical Determinations
Fifty-two baboons (Papio hamadryas; 38 females and 14
males) were selected and studied at the Southwest National
Primate Research Center at the Texas Biomedical Research
Institute (San Antonio, TX). Baboons underwent a partial
resection (biopsy) of the pancreatic tail, followed by 14-
week treatment with either continuous i.v. EXE (Amylin,
San Diego, CA; Eli Lilly & Co, Indianapolis, IN) (0.014 mg/
kg body weight hour; n Z 26, 19 females and 7 males) or
saline (SAL; nZ 26, 19 females and 7 males). EXE or SAL
i.v. infusion was performed using heparin-coated poly-
urethane 7 French catheters that were placed in the internal
jugular veins under general anesthesia. These catheters were
routed s.c. to the interscapular region of the back, where the
catheters exited the skin into a molded plastic box (back-
pack) attached outside of a special jacket and were con-
nected to an infusion pump placed above the cage.39 After
catheter placement, baboons were housed in single indoor
metal cages with enrichment games and ad libitum access to
water and food, as previously described.36 All animal care140and procedures were approved by the Texas Biomedical
Research Institute Animal Care and the Use Committee as
well as the University of Texas Health Science Center at San
Antonio (San Antonio, TX), Institutional Animal Care and
Use Committee (protocols 1126PC and 1175PC). Anthro-
pometric and biochemical data were collected at baseline,
before the partial pancreatectomy/pancreatic biopsy, and
after 14 weeks of SAL or EXE infusion. Serum levels of
EXE were analyzed by AC2993 IEMA Assay (Amylin)
before and after treatment, as previously described.4
An additional cohort of 16 baboons, which had never
been exposed to any pharmacological treatment or surgical
procedures, was used as an additional control group. The
unmanipulated control animals were housed in two 6-acre
outdoor corrals. At necropsy, the pancreas of these baboons
was collected and the tail portion was divided from head/
body.
Surgery
Under general anesthesia, isoﬂuorane 1.5% v/v, the pancreas
was ﬁrst dissected along the inferior edge, exposing the
posterior avascular plane. The superior pancreas was then
dissected off the splenic artery and vein. The distal tail of the
pancreas was dissected away from the hilum of the spleen,
preserving the spleen. Ten percent to thirty percent of the
pancreas was removed. No drains were placed. Absorbable
interrupted sutures were used to close the fascia, and nylon
sutures were used to close the skin. During the same anes-
thetic procedure, heparin-coated polyurethane 7 French
catheters were placed in the internal jugular veins.
After the surgery, i.v. parenteral nutrition with 5%
glucose solution, potassium, and amino acids was provided
during a recovery period of 4 days, along with antibiotics
and analgesics. The perioperative/postoperative mortality
was 0%. Solid food was again introduced after the recovery
period, and baboons were housed inside individual cages
while on tether for treatment.
At the conclusion of the study, all baboons were hu-
manely euthanized by i.v. administration of an overdose of
sodium pentobarbital, 48 hours after cessation of the EXE or
SAL infusion, and necropsy was performed to collect the
head/body of the pancreas, as previously described.37,40
Pathological Data
Pancreas samples removed at baseline (tail) and at necropsy
(head-body) were ﬁxed in 10% neutral-buffered formalin,
embedded in parafﬁn wax, cut into sections (5 mm thick),
and stained with hematoxylin and eosin (H&E). The same
tissue collection and processing protocol was followed for
pancreas samples (tail and head-body) obtained from un-
manipulated control group. Two board-certiﬁed veterinary
pathologists (M.O. and E.J.D.), who were blinded to treat-
ment groups, evaluated pancreas slides to identify the
following: i) lesions consistent with acute or chronicajp.amjpathol.org - The American Journal of Pathology
Exenatide and Exocrine Pancreaspancreatitis (necrosis hemorrhage, suppurative inﬁltrates, or
ﬁbrosis), ii) ductal hyperplasia, and iii) ductal dysplasia.
Focal parenchymal or periductal mononuclear inﬂam-
matory cell accumulation (MICA)40 was evaluated in both
groups, and cells were also characterized using the mono-
clonal anti-CD68 (clone KP1; Dako, Carpinteria, CA),
anti-CD20 (clone L26; Dako), and anti-CD3 (clone PS1;
BioGenex, San Ramon, CA) antibodies, which identify
macrophages, B lymphocytes, and T lymphocytes, respec-
tively. Severity scores for MICA were as follows:
0 indicates none; 1 indicates minimal (<10 cells per focus);
2 indicates mild (<50 cells per focus or a single focus of up
to 100 cells); and 3 indicates moderate (>50 cells per focus
in more than one location).
Ductal hyperplasia was deﬁned as the presence of
columnar epithelium in small or midsized pancreatic ducts, in
the absence of any signiﬁcant architectural and cytological
atypia, and was scored as absent (0) or present (1). Columnar
epithelium seen in larger ducts was considered normal.
Acinar and ductal cell proliferation was evaluated by
Ki-67 immunostaining, using the monoclonal MIB-1 anti-
body (Dako). Acinar and ductal cell apoptosis was evalu-
ated using the monoclonal antibody M-30 (Roche,
Penzberg, Germany), which recognizes the caspase-cleaved
formalin-resistant epitope of cytokeratin 18. The number of
proliferating or apoptotic cells was evaluated by counting
the positive cells in a total of 1500 acinar and 150 ductal
cells per slide.
Electron Microscopy
For ultrastructural analysis, pancreatic samples from SAL
and EXE groups were ﬁxed for 2 hours at 4C in 2%
paraformaldehyde and 2% glutaraldehyde in 0.05 mol/L (pHTable 1 Anthropometric and Biochemical Characteristics of Study Pop
Clinical parameters SAL BAS EXE BAS SAL EOS EXE
Age (years) 10.9  4.7 10.8  6.9
Sex (M:F ratio) 7:19 7:19
BMI (kg/m2) 22.5  8.3 23.3  7.6 21.4  8.8 22
Waist (m) 0.48  0.1 0.5  0.2 0.47  0.1 0.4
FPG (mmol/L) 4.46  0.12 4.56  0.21 4.45  0.13 4.5
HbA1c
[% (mmol/mol)]
4.1  0.4
(21.3  4.4)
4.3  0.3
(23.5  3.3)
4.3  0.8
(23.5  8.7)
4
(23
Albumin (g/L) 39.1  1.0 39.1  1.1 36.0  1.0 36
ALT (mkat/L) 0.57  0.20 0.49  0.23 0.53  0.32 0.4
Amylase (mkat/L) 2.27  0.48 2.52  1.14 2.24  0.92 2.3
Creatinine (mmol/L) 90.2  3.5 92.8  3.5 85.8  3.5 84
Tot. Chol (mmol/L) 2.43  0.11 2.62  0.12 2.67  0.12 2.8
HDL (mmol/L) 1.06  0.04 1.14  0.05 1.09  0.06 1.1
LDL (mmol/L) 1.14  0.06 1.19  0.07 1.24  0.08 1.2
Trigly (mmol/L) 0.52  0.24 0.51  0.29 0.61  0.34 0.6
ALT, alanine transaminase; BAS, baseline; BMI, body mass index; EOS, end of stu
glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein
The American Journal of Pathology - ajp.amjpathol.org7.3) cacodylate buffer (Karnovsky ﬁxative), post-ﬁxed in
1% osmium tetroxide, and embedded in Epon-Araldite
(Sigma-Aldrich, St. Louis, MO). Thin sections were coun-
terstained with uranyl acetate and lead citrate. All samples
were examined with a Philips Morgagni electron microscope
(FEI Company, Eindhoven, The Netherlands).33Morphometric Analysis
Morphometric analysis was performed using the Computer
Assisted Stereology Toolbox (CAST) 2.0 system (Visio-
pharm, Ballerup, Denmark) coupled with an Olympus BX61
microscope (Olympus Corporation of the Americas, Center
Valley, PA). Duct morphometry was evaluated on H&E-
stained sections by using the stereology fundamentals pre-
viously described.33,34,41,42 Each ﬁeld had an area of
142,600 mm2 and was randomly selected from the whole
H&E section using the CAST meander sampling. On
average, we analyzed 142 ﬁelds per slide; in each ﬁeld,
point counting of total pancreatic tissue and ducts was
performed at the magniﬁcation of 40; 64 points were
inserted on each ﬁeld, and an average of 9090 points per
slide was used. The quantiﬁcation of the relative duct vol-
ume/% pancreas was calculated by using the following
formula: ðDP=TPÞ  100; where DP indicates points that
hit pancreatic ducts; and TP, total pancreas points. We also
quantiﬁed the following: i) total number of ducts, ii) total
duct area and volume, iii) ducts’ numerical density (number
of ducts/mm2), iv) total number of duct cells, v) average
duct cell size (mm2), vi) duct cells’ numerical density (duct
cells/1000 mm2), and vii) total duct mass (mg). All these
measurements were done before and after treatment, with
either SAL or EXE.ulation at Baseline and Study End
EOS
P value
SAL BAS vs
EXE BAS
SAL BAS vs
SAL EOS
EXE BAS vs
EXE EOS
SAL EOS vs
EXE EOS
0.45
0.89
.1  6.5 0.89 0.003 0.001 0.90
7  0.1 0.35 0.76 0.003 0.87
3  0.22 0.69 0.57 0.17 0.91
.3  0.6
.5  6.6)
0.08 0.06 0.30 0.98
.1  1.1 0.75 0.07 0.08 0.87
6  0.23 0.68 0.87 0.065 0.12
4  0.99 0.32 0.80 0.90 0.78
.9  3.5 0.65 0.044 0.047 0.81
0  0.13 0.35 0.13 0.15 0.47
7  0.08 0.2 0.60 0.80 0.45
7  0.08 0.55 0.02 0.24 0.76
9  0.34 0.96 0.037 0.043 0.75
dy; EXE, exenatide; F, female; M, male; FPG, fasting plasma glucose; HbA1c,
; SAL, saline; Tot. Chol, total cholesterol; Trigly, triglycerides.
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Figure 1 Pancreatic tissue weight and mononuclear inﬂammatory cell
accumulation (MICA) and ductal hyperplasia score changes in saline (SAL)
and exenatide (EXE) groups. A: Weight of pancreas (g) excised at baseline/
body weight (kg) at baseline. B:Weight of pancreas (g) excised at study end/
body weight (kg) at the EOS. C: Number of baboons with increase, decrease,
and no change in MICA score after EXE or SAL treatment. D: Number of an-
imals with pancreas MICA newly identiﬁed after SAL (white bar) and EXE
treatment (black bar). E: Number of baboons with increase, decrease, and no
change in ductal hyperplasia score after EXE or SAL treatment. F: Number of
animals with pancreatic hyperplasia newly identiﬁed after SAL (white bar)
and EXE treatment (black bar). Number of sections for each baboon Z 4
(H&E staining; 2 sections at baseline and 2 sections at the end of the study).
None of the comparisons were statistically signiﬁcant.
Fiorentino et alImmunoﬂuorescence Staining
Pancreas sections (5 mm thick) were ﬁxed and immuno-
stained as previously described.33,42 Nuclei were visualized
by staining with DAPI (Sigma-Aldrich). The following
primary antibodies were used: anti-insulin guinea pig
monoclonal (Dako), antiec-kit rabbit polyclonal antibody
(Cell Signaling, Beverly, MA), and MIB-1 mouse mono-
clonal antibody to detect Ki-67 (Dako).
Microscopy analysis was performed using a Zeiss
(Oberkochen, Germany) Axiovert 200 inverted ﬂuorescence
microscope equipped with a Retiga SRV charge-coupled
device camera (QImaging, Surrey, BC, Canada). Optical
sections covering the whole tissue section were acquired in
0.4-mm z-axis steps with the Zeiss Axiovert wideﬁeld
ﬂuorescence microscope and deblurred using the Nearest
Neighbor algorithm (Image ProPlus 6.2 3D Analyser; Media
Cybernetics, Rockville, MD).
Statistical Analysis
Anthropometric and biochemical parameters are expressed as
means  SEM or median (interquartile range) for variables
with a skewed distribution. Differences between groups were
assessed by unpaired Student’s t-test or by Mann-Whitney
test. Paired Student’s t-test and Wilcoxon test were used to
compare changes between baseline and end of study (EOS) in
each group. Comparisons between pretreatment and post-
treatment scores for SAL and EXE groups were performed
with two-sided Fisher’s exact test. To compare the changes
(basal-EOS) in the MICA and hyperplasia scores between
EXE and SAL groups, we used the two-sample Wilcoxon
rank test. P  0.05 was considered statistically signiﬁcant.
The changes in MICA and hyperplasia score, Ki-67, and
M-30epositive cell number were obtained by subtracting
pretreatment from post-treatment data. Statistical analyses
were performed with SPSS program for Windows version 17
(SPSS Inc., Chicago, IL). With a sample size of 52, two-sided
testing, and a type 1 error of 0.05, the study had power of
90% to detect a minimum difference of 20% in periductal
inﬂammation and ductal hyperplasia between groups,
considering that surgery may increase these parameters by
15%; as well as power of 95% to detect a minimum difference
in the number of acinar and ductal cells in proliferation (5 and
0.3 cells, respectively).
Results
EXE Treatment Is Not Associated with Increased Serum
Amylase Levels
The anthropometric and biochemical characteristics at
baseline and at the study end were not signiﬁcantly different
between EXE and SAL group (Table 1). At the EOS, serum
EXE levels in the EXE group were signiﬁcantly higher
(758  162 pg/mL) than in the SAL group (0.0 pg/mL).142Food consumption assessed during EXE and SAL infusion
was not signiﬁcantly different between both groups (EXE
versus SAL, 55.2  4.03 versus 53.6  2.6 Kcal/kg per day;
PZ 0.43), and no anorexia, vomiting, or behavior changes
were observed in EXE-treated animals as well as in SAL-
treated baboons.
We observed a signiﬁcant decrease in body mass index at
study end compared with baseline in SAL (21.4  8.8
versus 22.5  8.3 kg/m2; PZ 0.003) and EXE (22.1  6.5
versus 23.3  7.6 kg/m2; P Z 0.001) groups (Table 1).
EXE-treated baboons also showed a slight decrease in waist
circumference (0.47  0.1 versus 0.5  0.2 m; PZ 0.003).
Serum low-density lipoprotein increased modestly in the
SAL group and remained unchanged in the EXE group.
Interestingly, serum amylase levels did not change signiﬁ-
cantly after SAL and EXE treatment in comparison toajp.amjpathol.org - The American Journal of Pathology
Table 2 Pancreatitis, MICA, PanIN, and Hyperplasia Scores at Baseline and at the End of the Study
Variable
SAL BAS,
n Z 26
EXE BAS,
n Z 26
SAL EOS,
n Z 26
EXE EOS,
n Z 26
P value
SAL BAS vs
EXE BAS
SAL BAS vs
SAL EOS
EXE BAS vs
EXE EOS
SAL EOS vs
EXE EOS
Pancreatitis 0 0 0 0
MICA score
0 22 (84.6) 17 (65.4) 18 (69.2) 10 (38.5) 0.24 0.25 0.17 0.098
1 4 (15.4) 7 (26.9) 6 (23.1) 12 (46.2)
2 0 2 (7.7) 2 (7.7) 4 (15.4)
3 0 0 0 0
PanIN 0 0 0 0
Hyperplasia score
0 23 (88.5) 22 (84.6) 14 (53.8) 9 (34.6) 1.0 0.006 0.003 0.26
1 3 (11.5) 4 (15.4) 12 (46.2) 17 (65.4)
Data are given as number (percentage) unless otherwise indicated. All comparisons between EXE and SAL group were performed by Fisher’s exact test.
BAS, baseline; EOS, end of the study; EXE, exenatide; MICA, mononuclear inﬂammatory cells accumulations; PanIN, pancreatic intraepithelial neoplasia; SAL, saline.
Exenatide and Exocrine Pancreasbaseline [SAL, 2.24  0.92 versus 2.27  0.48 mkat/L
(P Z 0.80); EXE, 2.34  0.99 versus 2.52  1.14 mkat/L
(P Z 0.90)] (Table 1).
EXE Treatment Does Not Induce Pancreatic
Inﬂammation and Ductal Cell Hyperplasia
The weight of the pancreatic portion excised at baseline was
similar in the SAL and EXE groups (4.59  0.49 g versus
4.44  0.46 g; PZ 0.82), as was the weight of the pancreas
collected at study end (16.52  1.16 g versus 17.59  0.99
g; P Z 0.49) and total pancreatic weight (22.04  0.86 g
versus 22.12  1.05 g; PZ 0.5). In addition, no differences
between groups were observed when pancreas weight at
baseline and at study end was normalized for body weight
(P Z 0.9 and P Z 0.34, respectively) (Figure 1, A and B).
There was no histological evidence of lesions consistent
with pancreatitis (necrosis, hemorrhage, suppurative in-
ﬁltrates, or ﬁbrosis) either at baseline or after treatment with
SAL or EXE (Table 2). Some samples in both groups
exhibited minimal or mild focal parenchymal/periductal
MICA. CD3 immunostaining demonstrated that MICA was
mainly composed of T lymphocytes (Supplemental Figures
S1 and S2). At baseline, in the EXE group, 17 (65.4%), 7
(26.9%), and 2 (7.7%) of baboons had pancreatic MICA
scores of 0, 1, and 2, respectively, whereas in the SAL
group, 22 (84.6%), 4 (15.4%), and 0 baboons had pancreaticTable 3 Presence or Absence of MICA and Hyperplasia at Baseline an
Variables
No. of cases of newly identiﬁed MICA at study end
No. of samples without MICA before and after treatment
No. of samples with MICA at baseline
No. of cases of new identiﬁed hyperplasia at study end
No. of samples without hyperplasia before and after treatment
No. of samples with hyperplasia at baseline
All comparisons between EXE and SAL group were performed by Fisher’s exact
EXE, exenatide; MICA, mononuclear inﬂammatory cell accumulation; SAL, salin
The American Journal of Pathology - ajp.amjpathol.orgMICA scores of 0, 1, and 2, respectively (P Z 0.24)
(Table 2).
At study end, 18 (69.2%), 6 (23.1%), and 2 (7.7%) of
SAL group baboons had pancreatic MICA scores of 0, 1,
and 2, respectively. These scores were slightly, but not
signiﬁcantly, increased in comparison to baseline and likely
represent a surgery effect (P Z 0.25) (Table 2).
Also at study end, 10 (38.5%), 12 (46.2%), and 4 (15.4%)
of EXE-treated baboons had pancreatic MICA scores of 0, 1,
and 2, respectively. As observed in SAL group, MICA scores
after EXE treatment were slightly, but not signiﬁcantly,
increased (PZ 0.17) (Table 2). No signiﬁcant difference was
observed in MICA scores at the EOS between SAL- and
EXE-treated animals (PZ 0.089) (Table 2), and the change
(basal-EOS) in MICA score between the two study groups
was not statistically different (ZZ 0.546, PZ 0.585).
At study end, MICA score was increased in nine EXE- and
six SAL-treated baboons. There was a decrease of MICA
score in two baboons in both groups and no change in 15
EXE- and 18 SAL-treated baboons (PZ 0.50) (Figure 1C).
We analyzed the 17 EXE- and 22 SAL-treated baboons
without exocrine pancreas MICA at baseline (score, 0). At
study end, newly identiﬁed MICA was observed in eight
EXE- and in six SAL-treated baboons, demonstrating that
EXE did not induce a signiﬁcant increase in new pancreatic
MICA compared with SAL (P Z 0.31) (Table 3 and
Figure 1D).d after Treatment in EXE and SAL Groups
EXE, n Z 26 SAL, n Z 26 P value
8 6 0.31
9 16 0.31
9 4 0.49
14 9 0.21
8 14 0.21
4 3 1.0
test.
e.
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Figure 2 Exocrine pancreas electron micro-
scopy. Electron microscopic analysis conﬁrms the
presence of lymphocytes (asterisks) among
exocrine acinar cells in both saline (SAL) and exe-
natide (EXE) groups, at baseline and at the study
end. Acinar cells are morphologically normal
appearing with regular nuclei, abundant endo-
plasmic reticulum, and zymogen granules, before
and after EXE treatment as well as before and after
SAL treatment.
Fiorentino et alThe relative risk of an increase in MICA score and the
onset of MICA in the EXE group was 1.5 (95% CI,
0.6e3.5; P Z 0.5) and 1.7 (95% CI, 0.7e4; P Z 0.3)
compared with SAL group. Collectively, these data suggest
that EXE treatment did not signiﬁcantly increase the risk of
developing or aggravating the extent of pre-existent MICA.
The presence of ductal cell hyperplasia and dysplasia in
EXE and SAL groups was investigated by histological
analysis (Supplemental Figure S3). Notably, no dysplastic
lesions, pancreatic intraepithelial neoplasia (PanIN), or le-
sions resembling pancreatic cancer were observed in any
pancreatic specimen examined at baseline or after treatment
in either animal group43,44 (Table 2).
No difference in ductal hyperplasia score was observed at
baseline between the EXE and SAL groups (P Z 1.0)
(Table 2). At study end, the number of samples with ductal
hyperplasia was increased in the SAL [12 (46.2%) versus 3
(11.5%); P Z 0.006] and EXE [17 (65.4%) versus 4
(15.4%); P Z 0.003] groups in comparison to baseline
(Table 2), suggesting a signiﬁcant effect of the surgery on
ductal cell proliferation as a physiological attempt of the
remnant pancreas to compensate for the partial pancreatic
resection. Hyperplasia score at the EOS was not signiﬁ-
cantly different between SAL and EXE group (P Z 0.26)
(Table 2), and no signiﬁcant difference was observed be-
tween both groups in the change of hyperplasia score from
baseline to the study end (Z Z 0.943, P Z 0.346).
The hyperplasia score increased after EXE or SAL
treatment in 14 and 9 baboons, respectively (PZ 0.21), and
did not change in 11 EXE- and 17 SAL-treated baboons
(Table 3 and Figure 1, E and F). At study end, the hyper-
plasia score was decreased (from 1 to 0) in one baboon from144the EXE group. The relative risk of a hyperplasia score
increase was 1.6 (95% CI, 0.86e3.0; P Z 0.2) in EXE-
treated baboons compared with SAL. Therefore, EXE did
not signiﬁcantly increase the risk of ductal hyperplasia.
We also evaluated sex-speciﬁc changes in MICA and
hyperplasia score and observed that EXE treatment did not
signiﬁcantly affect MICA or hyperplasia score in males or
females (Supplemental Table S1).
In addition, we analyzed pancreatic tail and head/body por-
tions collected from a separate cohort of 16 baboons (8 males
and 8 females) that were not treated with SAL or EXE.Notably,
we observed different stages ofMICA and ductal hyperplasia in
some of the pancreatic tail and head/body samples and no
signiﬁcant differences inMICA and hyperplasia scores between
the EXE, SAL, and control groups, suggesting that MICA and
ductal hyperplasia are physiologically present in baboon
exocrine pancreas (Supplemental Table S2).
Electron microscopic analysis conﬁrmed the presence of a
few lymphocytes among acinar cells at baseline and at the
study end in both SAL and EXE groups. Acinar cells were
morphologically normal appearing, showing regular nuclei,
abundant endoplasmic reticulum, and numerous zymogen
granules at both baseline and after either EXE or SAL
treatment (Figure 2).
EXE Does Not Signiﬁcantly Affect Baboon Pancreas
Acinar and Ductal Cell Proliferation
The number of Ki-67epositive acinar cells did not differ be-
tween the EXE and SAL group at baseline (PZ 0.14) and at
the study end (PZ 0.07). Interestingly, it also did not change
signiﬁcantly between baseline and EOS in the SAL groupajp.amjpathol.org - The American Journal of Pathology
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Figure 3 Exocrine pancreatic cell proliferation evaluation by Ki-67 immunostaining. A: Acinar cells positive for Ki-67 immunostaining (arrows). B: Mean
number of Ki-67epositive acinar cells in aline (SAL, white bars) and exenatide (EXE, black bars) groups at baseline and at the end of the study (EOS) (B). C:
Change in Ki-67epositive acinar cell number between baseline and EOS in both groups. D: Ductal cells positive for Ki-67 immunostaining (arrows). E: Mean
number of Ki-67epositive ductal cells in SAL (white bars) and EXE (black bars) groups at baseline and at EOS. F: Change in the number of Ki-67epositive
ductal cells between baseline and EOS in both groups. Number of sections with Ki-67 staining for each baboonZ 4 (2 sections at baseline and 2 sections at
the EOS). None of the comparisons were statistically signiﬁcant.
Exenatide and Exocrine Pancreas(PZ 0.87) and in the EXE group aswell (PZ 0.56) (Figure 3,
A and B). Moreover, the change in Ki-67epositive acinar cell
number from baseline to study end was not different between
SAL and EXE group (PZ 0.72) (Figure 3C).
The number of Ki-67epositive ductal cells at baseline
and at the study end was similar in the two groups
(P Z 0.40 and P Z 0.17, respectively). No signiﬁcant
difference was observed in the SAL group between study
end and baseline (P Z 0.77) (Figure 3, D and E). In
contrast, the number of Ki-67epositive ductal cells was
signiﬁcantly higher at study end than at baseline in EXE-
treated animals (P Z 0.04) (Figure 3, D and E). However,
the change of Ki-67epositive ductal cell number from
baseline to the EOS was not signiﬁcantly greater in the EXE
in comparison to SAL group (P Z 0.13) (Figure 3F).
EXE Treatment Does Not Affect Baboon Pancreas Acinar
and Ductal Cell Apoptosis
The number of M-30epositive acinar cells was not signif-
icantly different between groups at baseline (P Z 0.5) and
at the study end (PZ 0.08) and did not change signiﬁcantlyThe American Journal of Pathology - ajp.amjpathol.orgafter SAL (P Z 0.17) or EXE (P Z 0.37) treatment
(Figure 4, A and B).
Accordingly, the change in M-30epositive acinar cell
number from baseline did not differ signiﬁcantly between
SAL- and EXE-treated baboons; P Z 1.0) (Figure 4C).
The number of M-30epositive ductal cells was also not
signiﬁcantly different between SAL and EXE group at base-
line (PZ 0.33) and at the study end (PZ 0.1), and did not
change signiﬁcantly after SAL (PZ 0.17) or EXE (PZ 0.34)
treatment (Figure 4, D and E). In addition, the change in
M-30epositive ductal cell number at study end did not differ
signiﬁcantly between groups (PZ 0.11) (Figure 4F).Quantitative Duct Analysis by CAST
When comparing the quantitative effects of SAL and EXE on
duct morphometry, there were no statistical differences be-
tween groups before and after treatment as well as between the
delta-changes between groups in duct numerical density
(P Z 0.71 and P Z 0.83, respectively) (Supplemental
Figure S4, A and B), relative duct volume/% pancreas
(P Z 0.53 and P Z 0.61, respectively) (Supplemental145
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Figure 4 Exocrine pancreatic cell apoptosis evaluation by M-30 immunostaining. A: Acinar cells positive for M-30 immunostaining (arrows). B: Mean
number of M-30epositive acinar cells in saline (SAL, white bars) and exenatide (EXE, black bars) groups at baseline and at end of the study (EOS) (B). C:
Change in M-30epositive acinar cell number. D: Ductal cells positive for M-30 immunostaining (arrows). E: Mean number of M-30epositive ductal cells in SAL
(white bars) and EXE (black bars) groups at baseline and at EOS. F: Change in the number of M-30epositive ductal cells. Number of sections with M-30
immunostaining for each baboon Z 4 (2 sections at baseline and 2 sections at the EOS). None of the comparisons were statistically signiﬁcant.
Fiorentino et alFigure S4, C and D), duct cell size (PZ 0.32 and PZ 0.98,
respectively) (Supplemental Figure S4, E and F), duct cell
numerical density (P Z 0.47 and P Z 0.51, respectively)
(Supplemental Figure S4, G and H), and total duct mass
(P Z 0.78 and P Z 0.82, respectively) (Supplemental
Figure S4, I and J). These data are consistent and reinforce
the semiquantitative/qualitative data on ductal cell
hyperplasia.
EXE Treatment Promotes the Differentiation of Ductal
Cells Toward a b-Cell Phenotype
It has been reported that EXE promotes the proliferation and
differentiation of b-cells from ductal progenitor cells in
rodents.1,3,45 We, therefore, used triple-immunoﬂuorescence
staining to evaluate the presence of insulin-positive cells in
association with markers of cell proliferation (Ki-67) or
cell transdifferentiation (c-kit) in pancreatic ducts. Prolif-
erating Ki-67epositive nuclei in duct structures were rare
in both the EXE and the SAL groups, and costained
occasionally with insulin (Figure 5A and Supplemental
Figure S5A). Interestingly, only in the EXE group at
study end, we detected some c-kitepositive cells co-
expressing insulin in large duct structures (Figure 5B and146Supplemental Figure S5B), thus suggesting that EXE may
promote transdifferentiation of ductal cells to insulin-
producing cells.Discussion
The clinical literature on the association between pancreatitis,
pancreatic cancer, DPP-IV inhibitors, and GLP-1 receptor
agonists is controversial and does not allow ﬁrm con-
clusions.8,12e25 Animal studies have also provided contra-
dictory data in relation to inﬂammation, proliferation, and
metaplasia in exocrine pancreas. More important, in none of
these studies, there was a direct comparison between pre-
treatment and post-treatment pancreas in the same ani-
mals.26e31 The Food and Drug Administration and the
European Medicines Evaluation Agency have recently re-
analyzed all studies on GLP-1 receptor agonist and DPP-IV
inhibitors and concluded that there is no signiﬁcantly
increased risk of either pancreatitis or dysplastic lesion/
pancreatic cancer in rodents, nonhuman primates, and humans,
but suggested continuous monitoring of these drugs.46
Herein, we examined the effects of EXE treatment on
exocrine pancreas of nonhuman primates, performing aajp.amjpathol.org - The American Journal of Pathology
Figure 5 Detectionof insulin-expressing cells in pancreatic ducts by immunoﬂuorescence staining.A:Representative images of pancreas sections triple stainedwith
insulin (red), Ki-67 (green), andDAPI (blue), at baseline and at study end, in saline (SAL) and exenatide (EXE) groups. After pancreatectomy (EOS), Ki-67epositive nuclei
(arrows) were found in duct structures of either the SAL or EXE group. B: Representative images of pancreas sections triple stained with insulin (red), c-kit (a marker of
differentiation)(green),andDAPI(blue)atbaselineandatstudyendinSALandEXEgroups.Rarecellsdouble labeledwithc-kitandinsulin(yellowstaining)were identiﬁed
in duct structures only at study end in the EXE group (arrows). Examples of c-kitepositive ductal cells co-expressing insulin are also shown at higher magniﬁcation. The
boxed areas in white in the SAL- and EXE-treated samples are magniﬁed in the single channel and overlay photos on the right. Original magniﬁcation,2.5.
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Fiorentino et aldirect comparison between samples taken before and at the
end of treatment.
Interestingly, 14-week EXE continuous infusion was not
associated with an increase in amylase levels or pancreatic
mass, which are indirect indicators of pancreas inﬂamma-
tion/pancreatitis.
Although serum EXE levels in EXE-treated baboons
were fourfold higher than those achieved in diabetic-treated
patients,4 there was no evidence of acute or chronic
pancreatitis (necrosis, hemorrhage, suppurative inﬁltrates, or
ﬁbrosis). Focal parenchymal or periductal MICA, which has
been described previously in nonhuman primates,37,40 was
observed in SAL and EXE groups and in control baboons,
and was not signiﬁcantly increased by EXE treatment.
We did not observe any evidence of PanIN, either before
or after treatment with either SAL or EXE.43,44 The ductal
hyperplasia score was increased by fourfold at the study end
compared with baseline in both groups; consistent with a
surgical effect, no signiﬁcant differences between SAL and
EXE group were observed. Moreover, ductal hyperplasia
was observed also in pancreas of control baboons with a
frequency not signiﬁcantly different from SAL and EXE
group. Although a trend toward an increase in hyperplasia
and MICA score was observed in EXE-treated animals, the
difference between SAL and EXE groups was not signiﬁ-
cant. Moreover, the presence of mononuclear inﬂammatory
cells in pancreatic parenchyma was not associated with an
impaired structural integrity of exocrine pancreas cells, as
assessed by electron microscopy. In addition, no histologi-
cal lesions suggestive of pancreatitis or ductal dysplasia/
PanIN were observed, and we only detected focal inﬂam-
matory cell accumulation (T cells) and simple hyperplasia in
the absence of any architectural and cytological atypia,
which represent subtle histological changes likewise
detectable in control group (ie, in physiological conditions).
The number of M-30epositive acinar and ductal cells
observed after EXE treatment by immunohistochemistry was
not signiﬁcantly different from baseline, demonstrating that
EXE does not affect exocrine pancreatic cell apoptosis. The
number of Ki-67epositive acinar cells did not change signiﬁ-
cantly after treatment in the EXE group. Ki-67epositive ductal
cell number after EXE treatment was slightly increased
compared with baseline; however, the change of Ki-67e
positive ductal cell number at study end from baseline was not
signiﬁcantly different betweenEXEandSALgroup. To analyze
in greater depth the effect of EXE on pancreatic ducts, duct
morphometric analyseswere also performedbyCAST.33,34,41,42
No signiﬁcant changes in ducts’ numerical density, relative duct
volume/% pancreas, ductal cell size, ductal cell numerical den-
sity, or total duct mass were observed at the EOS in comparison
to baseline in EXE- and SAL-treated baboons.
In consideration of previous data reporting the effect of
GLP-1 in promoting the proliferation and transdifferentiation
of b-cells from ducts, we evaluated whether EXE treatment
was associated with a differentiation of ductal cells toward a
b-cell phenotype.1,3,45,47,48 Interestingly, only in EXE group at148study end, some c-kit (a marker of transdifferentiation) posi-
tive cells co-expressing insulin were detected in large duct
structures, suggesting that EXE may promote the differentia-
tion of ductal progenitor cells to insulin-producing cells.
However, the evaluation of EXE effects on b-cell mass and
secretion was not the goal of this study, and additional studies
are required to conﬁrm and evaluate in-depth GLP-1 receptor
agonist actions on b-cell neogenesis from ductal progenitor
cells in nonhuman primates and in diabetic patients.
Baboons represent an interesting nonhuman primate
model to study human diseases because of their genetic and
pathophysiological similarity to humans.32e38,40,42 Because
the incidence of pancreatitis in baboons is similar to humans,
these ﬁndings may have an impact on clinical practice.9,37
The strengths of the present study are its relatively large
sample size considering that it was conducted in large
nonhuman primates, a direct comparison between pancreatic
samples taken before and at the end of the treatment in the
same animals, a semiquantitative histological evaluation of
pancreatic inﬂammation and hyperplasia performed by two
veterinary pathologists who were blinded to treatment
groups, a quantitative analysis of exocrine pancreatic cell
turnover, and a quantitative analysis of pancreatic ductal
mass by CAST. Although some toxicologists prefer to avoid
the blinded examination,49 we elected to evaluate pancreatic
slides in blind to avoid biases in underestimation or over-
estimation of any negative effect of EXE treatment.
This study has some limitations, including a medium
duration dosing time (3.5 months) and the lack of a recovery
group, whichmay limit us to detecting small effects of EXE on
exocrine pancreas. However, the high serum EXE levels in
treated animals could be sufﬁcient to detect some potential
negative effects of the drug. The comparison of different
portions of pancreas may represent a limitation of the study;
however, although islet of Langerhans distribution is different
between tail and body/head, no differences in exocrine tissue
histological features exist between tail and body/head.
In conclusion, we did not observe a signiﬁcant associa-
tion between EXE treatment and pancreatic inﬂammation
and/or ductal hyperplasia/dysplasia in nonhuman primates.
Our data also provide preliminary evidence suggesting that
EXE may promote the differentiation of pancreatic ductal
cell toward a b-cell phenotype in baboons and possibly in
humans affected by type 2 diabetes mellitus. However,
further studies of longer duration are needed to conﬁrm the
long-term safety of EXE treatment and the capability of
GLP-1 receptor agonists to promote the transdifferentiation
from ductal cells to b-cells, in nonhuman primates.Acknowledgments
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